Prior to Indigo, Kathryn was Investment Principal at the Massachusetts Clean Energy Center (MassCEC) where she invested in enterprise and consumer-facing clean energy companies, including software and hardware companies focused on utility and grid resilience, grid edge, next-generation renewables, efficient mobility, industrial efficiency, sustainable buildings, and the water-energy nexus. Soumya has more than two decades of experience in structure-based drug design and molecular modeling both in the areas of small molecules and biologics across multiple target classes and indications. Matthew works on both public and private investments and serves as a Board Director for Cerebral Therapeutics, DTx Pharma, Emergence Therapeutics, Forge Biologics, Jnana Therapeutics, and Kira Pharmaceuticals. Maryann Vigliotta is the Vice President of Operations and HR at RA Ventures (RAVen). At Corning, he held a number of sales and marketing roles with increasing responsibility; in his last position at Corning, Cony was responsible for marketing at a new business unit focused on high-throughput screening and molecular biology products. Mike is President and Chief Executive Officer of Sionna. Peter Kolchinsky, Ph.D. - Forma Therapeutics Michael has more than two decades of experience in immuno-oncology and immunology research in both large pharma and biotech settings. Peter Kolchinsky is a founder and Managing Partner at RA Capital Management and author of The Great American Drug Deal. Her graduate research investigated synaptic translation in syndromic autism. Kriti Subramanyam is an Associate within the TechAtlas division of RA Capital Management. Tom holds a BS in Health Sciences with a minor in Journalism from Northeastern University. He also holds a B.A. Prior to joining RA Capital, Mario was Associate Vice President for Advanced Research at Sanofi Pasteur and Head of the team executing a strategy for integrating influenza vaccine development with machine learning and antigen design. Kriti holds a B.S. Matt comes to RA from Localytics where he served as a Senior Software Engineer for the past two years. He holds BA and MA degrees in immunology from the University of Cambridge, an MD from University College London, and an MAS in clinical research from UCSF. Michael Sherman is a Venture Partner at RA Ventures. Prior to Catamaran, Mark served as Vice President, Legal Affairs at Rubius Therapeutics where he was responsible for leading internal legal activities in support of Rubius IPO and its growth to a clinical-stage company. Prior to RA Capital, Tom worked as an Associate at Flagship Pioneering. Alonso was also a chemistry professor at the Universidad de los Andes in Colombia. April 28, 2023 Updated: April 28, 2023 4:29 p.m. 8. Angela's primary responsibilities at RAVen are to lead development and oversee implementation of best practices in clinical strategies in RA's newcos and portfolio companies. Pieter previously worked as a consultant with McKinsey & Company, where he managed a variety of healthcare engagements, including pharmaceutical mergers, biotech product launch plans, OTC product rationalization, and hospital acquisitions.
Jungkook Sasaeng Information,
Berkshire Pigs For Sale Florida,
Pyramids Built On Same Latitude,
Articles P